Batu Biologics Successfully Completes $1.3 Million #Starvethetumor Equity Crowdfunding Campaign
Company Intends to Aggressively Pursue Clinical Development of Angiogenesis Targeting Immunotherapy Product ValloVax
Batu Biologics, an immuno-oncology Company dedicated to the development of its clinical stage tumor-angiogenesis targeting immunotherapy, ValloVax™, announced today the successful closure of a regulation 506(c) equity crowdfunding offering bringing in $1.3 Million in capital to the Company.
